Glaukos

Update in progress

GKOS (NYSE)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Glaukos is an ophthalmic pharmaceutical and medical technology company developing therapies for glaucoma, corneal disorders, and retinal diseases. It markets iStent devices to restore natural aqueous outflow in open-angle glaucoma, including iStent inject W and iStent infinite, and iDose TR to reduce intraocular pressure. It also develops iLink for keratoconus and ILution for transdermal eyelid delivery, plus the retinal XR platform for AMD. Sells through direct sales to ASCs, hospitals, and practices. Formerly Transdx; founded 1998; based in Aliso Viejo, CA.

Company score

Sentiment: 0.48; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.41; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.14; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.31; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive